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The growth of cultured human keratinocyres (KC) is inhib-
ited by garnma interferon (IFN-y). cyclosporin A and trans-
forming growth factor-heta, but not by tumor necrosis factor. 
When these anti proliferative molecules were added to KC 
they induced a conceneration and time-dependent inhibition 
oE12SI-epidermal growth factor (I-EGF) binding. These an ti-
proliferative molecules primarily reduced the number of 
binding si res by approximately 25% - 50% wirhoU[ affecting 
T wo of the most important mitogcns for culrured human keratinocyrcs (KC) are epidennal growth fac-tor (EGF) and insulin-like growth facror-f/somato-medin-C (SM-C) rl-4J. In contrast, other molecules sllch 3S gamma interferon (IFN-y), cyclosporin A 
(CsA). and transforming growth factor-beta (TGF-p) inhibit KC 
proliferation [3,5,6]. However, the precise molecuJar mechanism 
responsible for growth inhibicion has not been elucidated. Because: 
the binding of either EGF or transforming growth factor-alpha 
(TGF-a) to the EGF receptor initiates a variery of metabolic events 
leading to KC proliferation r7J, we sought to determine whether 
IFN-}'. CsA, and TGF-pcould modulate the ligand binding ofiodi-
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Abbreviations: 
CsA: cyclosporin A 
EBSS: Earlc's balanced salt solution 
ICAM-l: intercellu lar adhesion molecule~l 
I-EGF: '2~I-Epidcrmal growth factor 
I FN~O': alpha interferon 
IFN-y: gamma interferon 
K.UM: ker;lrinocyte hasal medium 
K C: keratinocytcs 
KGM: keratinocyte growth medium 
PK-C: protein kinase C 
SM-C: sol11atomedin~C 
T G F-a: transforming growth factoh;Llpha 
TGF~P: transforming growth factor~ber.a 
TNF: rumor necrosis ractor~31pba 
the binding affinity. Tumor necrosis factor did not influ-
ence the Ligand binding by I-EGF. In parallel with the ability 
of the anriproiiferarivc molecules to inhibit I-EGF binding, 
there was an increase in transforming growth faccor-alpha 
production. These results suggest that several different anti-
proliferative molecules may share a common mechanism to 
inhibir cell growth by reducing I-EGF binding to KC.j [liVest 
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nared-EGF (J-EGF) to the EGF cell surface receptor, and thereby 
mediate the antiproliferative action of these molecules. We also 
stUdied tumor necrosis factor (TN F), because it can induce KC 
intercellular adhesion molecule-l (JCAM-l) expression but does 
nOt inhibit proliferation [7.8J. 
Other investigators have demonstrated that tbe EGF receptor is a 
target for modulation that complemems the biologic proliferative 
responses mediated by a variety of molecules on a diverse array of 
cultured cell types. Some of the anciproliferative molecules and cell 
rypes that have been reported to show down modulation of ligand 
binding include IFN-a on Madin-Darby bovine kidney cells 19]' 
IFN-r on endothelial cdls [to]. and TGF-p on human umbilical 
endothel ial cells {I I] and fibroblasts {12.13]' Furthermore. activa-
tion of protein kinase C (PK-C) by phorbol esters in KC has led to 
growth arrest, differentiation, and decreased EGF receptor expres-
sion 114 ,15]. Thus, there appears to be a relatively good correlation 
between (he ability of a molecule to inhibit cell growth and down 
modulation of EGF receptors. To extend our earlier observation 
that there was an inverse correlation between down modularion of 
EGF receptors associated with increased TGF-a production [16]. a 
detailed analysis ofTGF-a production was also performed. 
MATERIALS AND METHODS 
Keratinocytc C ultures Primary KC cultures were obtained from 
normal appearing skin of volunteers without any skin disease by 
using a keratome and preparing a single cell suspension as previously 
describrd Pl. The fresh epidermal cel ls were seeded intO 35-mm 
plasric petri dishes (Lux, Flow Laborarories. Naperville. IL) and 
grown in the presence of a low calcium, serum free medium con-
taining EGF (10 ng/ ml). insulin (5 }1g/ ml) , hydrocortisone (0.5 
,ug/ml), bovine pituitary extract 0.4% v/v, and penicillin (100 
units/ml), streptomycin (100 ug/ ml), and amphote ricin B (0.25 
I'g/mI) designated KGM (Cloneties Corp., San Diego. CAl as pre-
viously described [3J. For some procedures. a KC basal medium 
(KBM, Clonetics) was utilized chat does not contain any growth 
factors. The KC were passaged routinely using 0.03% trypsin/ 
0.01 % EDTA. and KC between passage number 3 and 7 were wed. 
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The KC w~re mai.ntained in a humidified incuba[Qr at 37°C with 
5% CO,j95% air. 
Growth Mod1l1ating Molecules Receptor grade EGF was pur-
chased from Collaborative Research, Inc. (Bedford. MA). Recombi-
nant IFN-yand TNF-a were obtained from Dr. M. Shepard (Gene-
tech. Inc .. S. San Francisco, CA) and had specific activities of 
3 X 10' U/ mg and 5 X 10' U/ mg, respectively. The specific activ-
jcy of the lFN-y was monirored using a sensitive r41dioimmunoassay 
procedure (Centocor, Mdvern, PA), and the TNF activity was 
monitored using a standard cytotoxiciry bioassay employi.ng LM 
cel ls as targets as previously described [17J. CsA was obtained from 
Sand.oz Research Institute (East Hanover, N]), and stock solutions 
in dimethylsulfoxide were freshly prepared for each experiment. 
TGF-pwas purchased from Collaborative Research, Inc., and stored 
in sialinized glass rube aliquots ar -20°C. When rhe KC were 
subconfluent, the IFN-,.. CsA, or TGF-fJ was added, and this addi-
non was defined as the time zero point. 
Ligand Binding Assay J~EGF was purchased from Collaborative 
Research. Inc. (specific activ ity = 103 - 141 ,uCi/ug). In a staJ)-
dard binding assay, 1.5 - 2.5 X l OS KC in 24-well plates were 
washed rwice w,ith KBM at 37°C (1 ml each at an interval ofl .S b). 
T he cells were washed once wirh Earle's balanced salt solution 
(£BSS) containing 0.2% bovine serum albumin (R LA grade, Sigma 
Chemical Co.). The cells were chi lled on an ice batb and then 
incubated with 0.4 ml of medium composed of EBSS with 0.2% 
bovine serum albumin (binding medium) and varied concentrations 
of l-EGF (0.032 to 3.2 nM). The cultures were then assayed ar 4"C 
for I-EGF binding capacity. After 6 h, the assay was terminated by 
washing the monolayerS 3 rimes with 1.5 ml ice-cold binding me-
dium, solubilization of cells in 1 m1 of 0.1 N sodium hydroxide 
containing 1 % 50S. and cOUnting in a gamma counter [t 8]. Non-
specific binding was derermined by adding a 200-fold excess of 
unlabeled EGF to parallel sample wells and was no greater than 5% 
of the total amou.nt bound under any treatment condition. Data 
points represent the average of duplicate samples with nonspecific 
binding subtracted. Each fi gure represents the mean of four separate 
experiments. The sundard error of the mean Wa!. less than 10% for 
all experiments. 
M,easurement ofTGF-a: Protein To determine the amount of 
TGF~O' produced by cultured KC. rhe conditioned medium from 
semi-confluent KC maintained in either RGM or EBSS containing 
0.2% bovine albumin was assayed for TG F-Q concentration using a 
radioimmunoassay kit (Biotope, Seattle, WA) as previously de-
scribed 116]. Briefly. duplicate 100-,u1 aliquots were removed and 
immediately reduced and denatured. A standard curve was per-
formed using the provided pure TGF-a at five different concentra-
tions. There was no cross-reactivi ty of the TGF-a assay for EGF up 
to 1 ,ug/ mL The results represent the mean of nve different experi-
ments and the scand.1rd error of the mean was Jess than 10%. 
RESULTS 
lFN-i'. CsA and TGF-P. but not TNF Decrease Binding of 
I-EGF to Keratinocytes T he ability of l'FN-y, CsA, TGF-fJ, and 
TNF to modulate I-EGF bindjng was srudied ar concentrations 
known to influence cultured KC behavior f3 -6.8]' Hence, the anti-
proliferative concentrations utilized in the ligand binding stUdies 
were 10- 10' U / ml for IFN-Y; 2.5-10 I'g/ ml for CsA; 12 - 24 
ng/ ml for TGF-fJ; and 500- 10' U/ ml for TNF. To compare the 
rehtive abi lity of these various molecules to influence keratino-
eytes, the calculated molar concentration of a representative amount 
is provided: 10 U/ ml oflFN-Y = 0.71 nM; 5l'g/ml of CsA = 4.2 
11M; 24 ng/ ml TGF-fJ= 0.9 nM; 500 U/ml of TNF = 4.2 nM. 
The relative ability of these molecules to influence KC behavior in 
these experiments was the same as we have previously reporred (data 
not shown). Because the densi ty of cells rn.ay influence EGF recep-
tor expression \19], the seeding density ofKC were adjusted to take 
into account the relarive anti proliferative effects of various mole-
cules, so that at the time of ligand binding, there were approxi-
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Figure 1. Maximal1-EGf binding is inhibitied by 48 h of exposure with 
IFN-y (100 U/ ml. tritl"g/~s) . CsA (5 ,ug/ ml , open rire/es), and TGF~p (24 
flg/ml, dased rircfes) comp2red to untreated KC cu lwres (squtlra). 
mately equivalem numbers of cells that were at subcon£luency 
(1.S -2.5 X 10!> cclls/24 well dish) . Because the KC were grown in 
EGF containing KGM, it was necessary to wash the cells with EGF-
free KBM for 3 h at 37°C to remove the EGF (da ta not shown). The 
binding of I-EGF was performed on ice bath ro minimize imernali-
zarion. intracellular degradation, and release or retenrion thon 
occurs at higher temperatures [201. Also, rhe binding of I~EGF at 
4 °C is rapid with rbe maximum level of cell-associated radioacrivity 
being reached by 4 h (da ta not shown). 
Figure 1. reveals the tesults of ligand binding with increasing 
concentrations of I-EGF to KC at 4°C in the presence and absence 
of anriproliferative molecules. However, using TNF at concentra-
tions which did not inhibit KC proliferation (500_ 101 U / ml, 
48 h), no decrease in I-EGF binding was observed (data nor shown). 
Scatchard transformation [21 J of these data resulted in linear plots 
(Fig 2) and the U GAND computer program indicates that rhe 
untreated KC had a dissociation constant (Kd) of 0.5 ± .1 t1M with 
76 ± 6 X 101 si t~s/~ell. ~ll an~iprolifera ti ~e tr~atments decreased 
the number of bmdmg SItes WIthout any stgnincant effecr on the 
Kd. The I-EGF receptor sices/ KC for IFN-y ttcatment were de-
creased to 43 X 103 , for CsA treatment they were decreased to 
38 X 10l, a.nd for TGF-p they were' decreased to 18 X 103 • 
The competition analysis between cold EGF and I-EGF is shown 
in Fig 3. This result confirms the specificity of the binding between 
unlabeled and labeled EGF. Furthermore, when IFN-y, CsA. or 
TGF-pwere added at the above concentrations simultaneously with 
the increasing concentrations of unlabe!edEGF. there was no influ-
ence on rhis reaction (data not shown), suggesting that these anti-
proliferadve molecules do nOt direccl y compete for I-EGF binding 
si res. 
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Figure 2. Scatchard plot of l-EGF saturation binding 2nalysis (or untreated 
KC culture!'. (SIl 14tlres) , lFN-jI (Irillll,gles) , CsA (Dptn drdts) , 2nd TGF-ft (dowl 
tides). 
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Figure 3. Competi tion analysis between non-radioactive EG F and I-EGF. 
Tho abi liry of CsA, IFN-y, and TGF-p to inhibit I-EGF binding 
to KC was dependent on the concentration of the annprohferaave 
ruoloculo (Fig 4). 
T he abiliry of CsA, IFN-y, and T GF-p at the a~ve concentra-
tions to inhibit I-EGF binding to KC was also time dependent. 
Figure 5 reveals that the rime-dependent inhibition .was fairlr s~mi­
lar among the different anti proliferative molecules, In that minimal 
inhibition on l-EGF binding was observed between 2 and 24 h. 
with the most. 5ubnancial decreases occurring between 24-48 h. 
Because EGF and TGF-Q compete for the same EGF receptor and 
cultured KC can produce TGF-a 171. we sought todirecdy measure 
the amount of T GF-a produced under our ligand binding condi-
tiol1!\. When aliquots were removed from the untreated KCcultures 
afte r the two EGF free KBM washes at 37°C. there was no detect-
able TGF-a. However, after 6 h of incubation at 4°C, there was 
0.25 ± .05 nM TGF-Ct: measured in the EBSS + 0.2% bovine albu-
min conditioned medium. Also. when 48 h IFN-y-treated KC cul-
tures were similarly examined. the same results v.:ere ob.tained. 
Thus. it did not' appear that increased TGF-O' productt?n dUr1?g ~he 
incubation period with I-EG F (4°C, 6 h) could explam the- slgru fi-
candy diminished I.EGF binding observed after IFN-y trea~~ent. 
To further examine this interaction, we performed two additional 
types of experiments. First, we ~ecrly a.dd~d 0.25 I~ o!TGFa at 
the same time we perfomlcd our ligand binding studies uSlllg I.-E~F 
and various concentrations of cold EGF and found no aire ratton III 
the subsequent binding events (data not shown). Second. we ~r­
formed a more detailed analysis of the kinetics ofTGF-a pr~ductJon 
and influence of IFN-y, CsA. and T6F-P on such producnon. 
Wben t .5 X l OS KC were maintained with t .5 ml of KGM and 
assayed for TG F-a production. with and without IFN-y. CsA, and 
TGF.p treatment at 37"C , there was approximately the sa~c 
amount ofTGF-O' produced during the fi rst 6 h as was measured 111 
K.BM at 4°C. However, after 12 h, both untreated and IFN-},-. 
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Figure • . Ability of CsA. IFN-y, and TGF-P to inhibit I-EGF binding is 
concentration dependent. 
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Figure 5. Killeli~ ofinhiLitioll ofl-EGF binding by rFN-}' (trirJngltS), ell\. 
(ope,. Cirr./~), and '!'GF-p (~/oJtJ rircl~): The x-a~iJ r~pre~nt5 the nme of 
mC'dium change with or without additIOn of annprohf('ranv(' molecul (' ~. 
CsA-. and TGF-p-treated KC produced increasing amounts of 
TGf. .. a. with the treated KC producing a significan tly greater 
amount between 24 -72 h (Fig 6). It should be noted that we have 
previously con.firmed that at the 48 h time point. the amount ?f 
TGF-a protein detected after lFN-}' treannent was also re£lected 10 
increased TGF-a mRNA production [16]. 
DISCUSSIO N 
These results indicate that exposure of cultured human KC to bio-
logically relevant concentrations of various anriprolife:rative. mole-
cules produces a decrease in ?inding by l-EGF. This e.ffect 15 both 
time dependent. concentration dependent. an~ speclfic. because 
TNF. which does nO[ inhibit growth (but does tnduce the appear-
ance of another cel l surface molecule . ICAM-l ). does not influence 
l-EGF binding. The primary effect of the ami proliferative mole-
cules on decreasing the relative number of EGF recept~rs. {rather 
than influencing the affiniry constant} by 56% to 24% .15 m good 
agreement with previous invcsciga.tors who have examtned o~her 
antiprol iferative responses on a vanery of cel.1 ryJ><:-s ~ summanzed 
in Table 1. Thus. all of these resuhs combtned indicate that the 
down modulation ofEGF receptors may be a generalized phenom-
ena by which antiproliferative molecules exert their effects on a 
varicry of cellular targets. Even though the cellular target. such as 
the KC. may ~ capable of producing its own TGF-a in an a~Jtocrine 
fashion, the down modulation of the EGF receptor would tnterfere 
with the ability of the cell to respond to this proliferative signal. The 
paradoxical effect of lFN-y-, CsA-! and TGF~.8-treated K<; i~cre~­
iog their T GF-a production, while decreasIng I-EGF bmding, IS 
8 
2 4 6 12 24 
HOURS 
Figure 6. Kint'{ics ofTGF-aproducrion by KC with IFN-y (trianglt'l), CsA 
(ltJ'C'1 drrles), and TG~-P (dostd c i ~dtS) vs untrea~cd cul~res (Ufl/Q~): The 
x-tlxiJ represents the: mile of medIum change with or " nhout addItIon of 
antiproliferuive molecules. 
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Table L Effect o f Antiproliferacive M olecules 011 Various Cell 
T ype I-EGF Binding 
Cell T ype Treatment Kd 
Keracinocytes - no trt:atm~nr 0.5 nM 
IFN-y (100 U/ ml) 0.3nM 
CsA (5 !lS/ ",I ) 
TGF-p (24 ug/ ml) 
MD.BK cells- nQ treatment 1.0 nM 
IFN-a (87 Vlml) 2.0nM 
NRK cells-no trt:atment 0,3 nM 
TGF-p (19 ng/ ml) 0.3 nM 
Enoothc:lial cdls- no treatmenr 1.4 pM 
TGF-p (I ng/ ml) 1.3 pM 
i'I' Sites/ 
Cell 
76,000 
43,000 
38,000 
18,000 
11.800 
7, 100 
6,000 
3,500 
64,000 
42.000 
Reference 
Currem 
Study 
Zoo .. " ,1191 
Massague 1131 
T,k,b= [I I] 
currently not completely understood. IFN-y, CsA, and TGF-ft do 
not directly compete for I-EGF ligand binding sites but influence 
t~e number of EGF cell surface receprors through another mecha-
nism. 
At least three possible different mechanistic scenarios can be con-
sidC" red to explain tbe observed relationships berween the anriprolif-
erarive molecules, T GF-a: production, and I-EGF binding in this 
KC culrure system. First, while the antiproliferative m olecules do 
not directly compete for J-EGF ligand binding sites, it was possible 
thar during tbe 6 h ligand binding assay at 4 "C, the anciproliferative 
molecules, despite having been washed away. could have con tinued 
to differentially increased KC TGF-a production. This newly pro-
duced TGF-a could then have competiti ,·eJy blocked the exoge-
nouslyadded I-EGF . This possibility can be exduded because there 
was only 0.25 nM TGF-a produced by the cultures during [his 6 h, 
and [here was no difference with or without IFN-r treatment. 
M oreover, when we added exogenously derived TGF-a (0.25 nM), 
there was no significant effect on the I-EGF ligand binding assay, as 
would have been predicted from tbe saturation binding data in 
Fig I. 
The other twO scenarios chat could explain our results are as 
follows. In the second, the anriproliferative molecules directly and 
primarily decrease EGF receptors: this is followed by a secondary 
compensatory increase in TGF-cx production by [he KCs. 
In the third , che antiproJife.rarive molecules directly and primar-
ily increase TGF-a production. whicb leads to a secondary ligand 
mediated EGF receptor in.ternalization and degradation {221. In this 
scenario, the antiproliferative moJecuJes wouJd also have to in£lu-
encr: some other post-receptor b inding event, because the "ner" 
effect of the treatment is anti proliferation. 
The second and third scenarios are somewhat more difficult to 
discern at present. Indirect evide.nce to support the second is that 
IFN-y can accivate PK-C !23J, which could p roduce direct down 
modulation and internalization/ degradation of the EGF receptor 
through phosphorylation of key amino acid residues [i4.15.22j. 
Other investigators have recently reported thar wben normal 
mouse mammary epithelial cells are transfected with an activated 
c-Ha-ras protooncogene. there is incre;tsed (five fold) TGF-a pro-
ducrion and a 60% reduction in l-EGFbinding 124]. However, these 
invcstigators, like ourselves, could nOt completely elucida.te 
whether their treatment ptimarily and directly increased TGF-a: 
production or whether the increased TGF-a production resulted 
secondarily from alterations primariJy centered around the down 
modulation of the EGF receptor. 
Work is undl:rway to further dissect thl: specific relationsh.ip 
between the anriproliferative molecules, TGF-a and EGF recep-
tors, on cultured KC. We are particularly interested in this phenom-
ena because we have recendy observed that in KC cultUred from 
psoriatic plaques, there are significant di.Jfr:rences in these molecuJar 
interactions wnich are preserved in vitro after multiple passages 
116]. The elucidation of these molecular details roay provide impor-
rant ncw insight into the pathogenesis of psoriasis, a disease charac-
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terized by KC b yperproliferarion, increased EGF receptor expres-
sion, TGF-a production., ;tnd c-Ha-tas expression [25 - 281. 
The aurho,-, ado:"owleagt hdp!ul aistussi01U IIlith Dr. R. Ntubig, Dr. G. Fisher, Dr. 
J. T. EIsler, Dr.)). Voo,h~s, and Dr.). Varani. Technical assiSlimu !.lIas provided 
b)' D. Gibbs. 
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AMERICAN BOARD OF DERMATOLOGY EXAMINATIONS 
In 1990. the Certifying Examination of the American Board of Dermatology will be held at 
the Hol iday Inn O'Hare Airport in Rosemont, lIlinois on November 4 and 5, 1990. The 
deadline for receipt of applications is May 1, 1990. 
The Dermacoparhology Special Qualification Examination will be held in Tampa, Florida on 
November 9, 1990. The de3dline for receipt of applications is July I , 1990. 
The next Examination for Specia,1 Qualification in Denru:{ological lmmunology j Diagnosric 
and Laborarory Immunology will be held in Rosemont. Illinois on November 1, 1991. The 
deadline for receipt of applications is April I, 199 1. 
For further information on these examinations, pleasecontacr: Clarence S. Livingood, M.D., 
Executive Director, American Board of Dermatology, Henry Ford Hospital , Derroit, MI 
48202. 
